ICP8 is the major DNA binding protein of herpes simplex virus type 1.
| Inventor | Institute |
|---|---|
| Roland Wolf | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| Cat. #: | 151029 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Microbiology |
| Application: | IHC ; IF ; IP ; WB |
| Target: | Herpes Simplex Virus Infected cell protein 8 (HSV-ICP8) |
| Reactivity: | Virus |
| Clone: | Array |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | ICP8 is the major DNA binding protein of herpes simplex virus type 1. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 51 kDa |
| Immunogen: | ICP8 purified from U-35-VERO cells. |
| Target background: | ICP8 is the major DNA binding protein of herpes simplex virus type 1. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Mohni et al. 2013. J Virol. 87(1):531-42. PMID: 23097436. Efficient herpes simplex virus 1 replication requires cellular ATR pathway proteins. Alazard-Dany et al. 2009. PLoS Pathog. 5(3):e1000340. PMID: 19282980. Definition of herpes simplex virus type 1 helper activities for adeno-associated virus early replication events. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.